ImmunityBio, Inc. Common Stock (IBRX) — Analysis Summary
ImmunityBio, Inc. Common Stock (IBRX) has a market cap of $11.14B with year-over-year revenue growth of +668.3%. Net margin stands at -310.2%. The stock trades at a P/E ratio of -11.2.
Key Takeaways
- Revenue changed +668.3% year-over-year
- Net margin of -310.2%
- P/E ratio of -11.2
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, IBRX posted revenue growth of +668.3% and trades at a P/E of -11.2.
ImmunityBio, Inc. Common Stock (IBRX)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -151.9% — severe operating losses
Net margin at -598.6% — losses exceed revenue (possible one-time charges)
Shareholder equity is negative, which can signal balance-sheet stress.
Net income fell 182.4% vs the prior period.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
691
Headquarters
SAN DIEGO, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.